CY1122169T1 - Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης - Google Patents
Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσηςInfo
- Publication number
- CY1122169T1 CY1122169T1 CY20191101076T CY191101076T CY1122169T1 CY 1122169 T1 CY1122169 T1 CY 1122169T1 CY 20191101076 T CY20191101076 T CY 20191101076T CY 191101076 T CY191101076 T CY 191101076T CY 1122169 T1 CY1122169 T1 CY 1122169T1
- Authority
- CY
- Cyprus
- Prior art keywords
- myelinosis
- treatment
- telomerase inhibitor
- methods
- myeloproliferative disorders
- Prior art date
Links
- 239000003277 telomerase inhibitor Substances 0.000 title abstract 2
- 229940123582 Telomerase inhibitor Drugs 0.000 title 1
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 title 1
- 229950004291 imetelstat Drugs 0.000 title 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 3
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Παρέχονται στο παρόν μέθοδοι για τη μείωση του πολλαπλασιασμού των νεοπλασματικών προγονικών κυττάρων και την ανακούφιση των συμπτωμάτων που σχετίζονται με άτομα που έχουν διαγνωστεί ή πιστεύεται ότι έχουν μυελοπολλαπλασιαστικές διαταραχές, όπως είναι η Ιδιοπαθής Θρομβοκυττάρωση (ΕΤ, Essential Thrombocythemia). Παρέχονται επίσης στο παρόν μέθοδοι για τη χρήση αναστολέων τελομεράσης για τη διατήρηση του αριθμού αιμοπεταλίων σε σχετικά κανονικό εύρος στο αίμα ατόμων που έχουν διαγνωσθεί ή υπάρχει υποψία ότι έχουν μυελοπολλαπλασιαστικές διαταραχές, όπως η ΕΤ.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261734941P | 2012-12-07 | 2012-12-07 | |
US201361799069P | 2013-03-15 | 2013-03-15 | |
US13/841,711 US9375485B2 (en) | 2012-12-07 | 2013-03-15 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
US201361900347P | 2013-11-05 | 2013-11-05 | |
PCT/US2013/070437 WO2014088785A1 (en) | 2012-12-07 | 2013-11-15 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122169T1 true CY1122169T1 (el) | 2020-11-25 |
Family
ID=50883867
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101076T CY1122169T1 (el) | 2012-12-07 | 2019-10-14 | Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης |
CY20201100568T CY1123206T1 (el) | 2012-12-07 | 2020-06-23 | Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100568T CY1123206T1 (el) | 2012-12-07 | 2020-06-23 | Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου |
Country Status (34)
Country | Link |
---|---|
EP (3) | EP3646876B1 (el) |
JP (5) | JP6433911B2 (el) |
KR (3) | KR102662590B1 (el) |
CN (2) | CN104936602B (el) |
AP (1) | AP2015008504A0 (el) |
AU (3) | AU2013356533B2 (el) |
BR (1) | BR112015013260A2 (el) |
CA (2) | CA2892907C (el) |
CL (2) | CL2015001530A1 (el) |
CY (2) | CY1122169T1 (el) |
DK (3) | DK3646876T3 (el) |
EA (1) | EA032973B1 (el) |
ES (2) | ES2789176T3 (el) |
FI (1) | FI3646876T3 (el) |
HK (2) | HK1210940A1 (el) |
HR (2) | HRP20191784T1 (el) |
HU (2) | HUE045098T2 (el) |
IL (2) | IL239266B (el) |
LT (3) | LT3456333T (el) |
MA (2) | MA45504B1 (el) |
ME (1) | ME03538B (el) |
MX (3) | MX2015007169A (el) |
MY (1) | MY180634A (el) |
NZ (1) | NZ708920A (el) |
PH (1) | PH12015501282A1 (el) |
PL (2) | PL2928477T3 (el) |
PT (3) | PT2928477T (el) |
RS (2) | RS60401B1 (el) |
SG (3) | SG10201802926XA (el) |
SI (2) | SI2928477T1 (el) |
TN (1) | TN2015000249A1 (el) |
UA (2) | UA117116C2 (el) |
WO (1) | WO2014088785A1 (el) |
ZA (2) | ZA201504124B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3296312T (lt) | 2004-07-02 | 2021-06-10 | Geron Corporation | Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė |
PL3065828T3 (pl) * | 2013-11-06 | 2019-06-28 | Mayo Foundation For Medical Education And Research | Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych |
TN2017000411A1 (en) | 2015-04-23 | 2019-01-16 | Geron Corp | Methods of polynucleotide preparation using multivalent cation salt compositions |
EP3318276A1 (en) * | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
NZ760873A (en) | 2017-07-28 | 2024-03-22 | Geron Corp | Methods of treating myelodysplastic syndrome |
IL278345B2 (en) * | 2018-04-30 | 2024-05-01 | Kartos Therapeutics Inc | Cancer treatment methods |
WO2021091904A1 (en) * | 2019-11-04 | 2021-05-14 | Geron Corporation | Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
CN1768075A (zh) * | 2003-01-31 | 2006-05-03 | 杰西·L·S·奥 | 使用苏拉明、戊聚糖多聚硫酸酯、端粒酶反义体及端粒酶抑制剂的方法和组合物 |
CN1244592C (zh) * | 2003-07-11 | 2006-03-08 | 暨南大学 | 抑制白血病细胞端粒酶活性的反义核酸及其应用 |
EP1667522B1 (en) | 2003-09-09 | 2018-01-17 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US20050282893A1 (en) * | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
LT3296312T (lt) | 2004-07-02 | 2021-06-10 | Geron Corporation | Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė |
FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2006113426A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
US20080021013A1 (en) | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
DK2101789T3 (en) | 2006-10-30 | 2015-03-23 | Geron Corp | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
CN101220044B (zh) * | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
-
2013
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en active Application Filing
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active IP Right Grant
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 MX MX2015007169A patent/MX2015007169A/es active IP Right Grant
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Application Discontinuation
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/me unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active IP Right Grant
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
-
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
- 2015-11-27 HK HK15111700.1A patent/HK1210940A1/xx unknown
-
2016
- 2016-01-08 HK HK16100186.6A patent/HK1212226A1/xx unknown
-
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
-
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
-
2019
- 2019-10-02 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
-
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142B2/en active Active
-
2021
- 2021-01-13 IL IL280144A patent/IL280144A/en unknown
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
-
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122169T1 (el) | Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CY1121076T1 (el) | Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες | |
CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
CY1120646T1 (el) | Προγονικα κυτταρα μεσοδερμικης προελευσης | |
CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
CY1118900T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
UY34538A (es) | Heteroarilos y usos de los mismos | |
BR112014028572A2 (pt) | calças absorventes descartáveis com características vantajosas de estiramento e capacidade de fabricação e métodos para fabricação das mesmas. | |
CY1118838T1 (el) | Ηρν-100 για χρηση στην αντιμετωπιση διαταραχων κατακρατησης αζωτου | |
CY1117620T1 (el) | Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης | |
UY34082A (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos | |
UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. | |
CY1118487T1 (el) | Αλατα σουλφονικου οξεος υποκατεστημενων με ετεροκυκλυλαμιδιο ιμιδαζολιων | |
EA201490562A1 (ru) | Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов | |
CY1118913T1 (el) | Νεοι ανθελονοσιακοι παραγοντες | |
CY1118645T1 (el) | Χρηση pidotimod στη θεραπεια της ψωριασης | |
UY34594A (es) | Derivados heterocíclicos bicíclicos, su preparación y su aplicación en terapéutica | |
UY34564A (es) | Utilización en terapéutica de derivados de imidazopiridina | |
EA201990799A1 (ru) | Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм |